Endothelin-1 and vasopressin plasma levels are not associated with the insertion/deletion polymorphism of the human angiotensin I-converting enzyme gene in patients with coronary artery disease

被引:7
作者
Al-Fakhri, N
Linhart, RE
Philipp, M
Heidt, M
Hehrlein, FW
Gardemann, A
Katz, N
机构
[1] Univ Giessen, Inst Clin Chem & Pathobiochem, D-35392 Giessen, Germany
[2] Univ Giessen, Cardiovasc Surg Clin, Giessen, Germany
[3] Otto Von Guericke Univ, Inst Pathol Biochem, Magdeburg, Germany
关键词
ACE I/D polymorphism; cardiovascular disease; renin-angiotensin system; endothelin; vasopressin;
D O I
10.1038/sj.jhh.1001519
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
The objective was to investigate whether the renin-angiotensin (RA) system and related peptides endothelin-1 (ET-1) and vasopressin (VP) influence the development of coronary artery disease (CAD). Angiotensin I-converting enzyme (ACE) insertion/deletion (I/D) gene polymorphism has been associated with the risk of CAD. The ACE I/D polymorphism determines ACE activity, but plasma levels of other RA system components remain unchanged. However, ET-1 and VP production could be increased by RA system-dependent stimulation, continually promoted by paracrine stimulation and sustained by neointimal growth. ET-1 and VP have not been associated with the ACE I/D polymorphism so far. The present study investigated the association of the ACE I/D polymorphism with plasma concentrations of ET-1 and VP, as well as with renin, angiotensin-II (AT-II) and ACE activity in 98 Caucasian individuals with CAD. ACE I/D polymorphism showed no association with plasma levels of VP, ET-1, AT-II or renin. These parameters were also not associated taking into consideration different patient variables, such as diabetes mellitus, hypertension or severity of CAD. Only plasma ACE activity was associated with the D allele. In conclusion, the ACE I/D polymorphism could not be related to plasma concentrations of VP, ET-1, renin or AT-II, but as previously demonstrated, it could only be related to ACE activity in patients with CAD. Differences in ACE activity between ACE I/D genotype subgroups are probably compensated within the RA system itself or within non-ACE pathways, so that plasma concentrations of the related peptides ET-1 and VP remain unaffected.
引用
收藏
页码:133 / 138
页数:6
相关论文
共 37 条
[1]   ACE gene polymorphism: Ischemic heart disease and longevity in 10150 individuals - A case-referent and retrospective cohort study based on the Copenhagen City Heart Study [J].
AgerholmLarsen, B ;
Nordestgaard, BG ;
Steffensen, R ;
Sorensen, TIA ;
Jensen, G ;
TybjaergHansen, A .
CIRCULATION, 1997, 95 (10) :2358-2367
[2]  
ALFAKHRI N, 1997, LANGENBECKS ARCH S1, V1, P25
[3]  
BENETEAU B, 1986, CLIN CHEM, V32, P884
[4]   CONTINUOUS IV ADMINISTRATION OF THE ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR ENALAPRILAT IN THE CRITICALLY ILL - EFFECTS ON REGULATORS OF CIRCULATORY HOMEOSTASIS [J].
BOLDT, J ;
MENGES, T ;
WOLLBRUCK, M ;
HARTER, K ;
HEMPELMANN, G .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1995, 25 (03) :416-423
[5]  
Braunwald E, 2001, HARRISONS PRINCIPLES, P1377
[6]   DELETION POLYMORPHISM IN THE GENE FOR ANGIOTENSIN-CONVERTING ENZYME IS A POTENT RISK FACTOR FOR MYOCARDIAL-INFARCTION [J].
CAMBIEN, F ;
POIRIER, O ;
LECERF, L ;
EVANS, A ;
CAMBOU, JP ;
ARVEILER, D ;
LUC, G ;
BARD, JM ;
BARA, L ;
RICARD, S ;
TIRET, L ;
AMOUYEL, P ;
ALHENCGELAS, F ;
SOUBRIER, F .
NATURE, 1992, 359 (6396) :641-644
[7]   Pressor and hormonal responses to angiotensin I infusion in healthy subjects of different angiotensin-converting enzyme genotypes [J].
Chadwick, IG ;
OToole, L ;
Morice, AH ;
Yeo, WW ;
Jackson, PR ;
Ramsay, LE .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1997, 29 (04) :485-489
[8]   Angiotensinogen (M235T) and angiotensin-converting enzyme (I/D) polymorphisms in association with plasma renin and prorenin levels [J].
Danser, AHJ ;
Derkx, FHM ;
Hense, HW ;
Jeunemaître, X ;
Riegger, GAJ ;
Schunkert, H .
JOURNAL OF HYPERTENSION, 1998, 16 (12) :1879-1883
[9]   Molecular genetics of the renin-angiotensin system: Implications for angiotensin II receptor blockade [J].
Davis, GK ;
Roberts, DH .
PHARMACOLOGY & THERAPEUTICS, 1997, 75 (01) :43-50
[10]   Anti-ischemic potential of drugs related to the renin-angiotensin system [J].
Ertl, G ;
Hu, K .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2001, 37 :S11-S20